Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has completed enrollment of the first 120 patients in its phase II oral insulin clinical trial, and has received permission from regulatory authorities in India to expand the trial enrollment from 120 patients to 140 patients.
Subscribe to our email newsletter
By expanding the trial, Emisphere will be able to evaluate the performance of all three active arms of the trial against each other for statistical significance. Without the additional patients, Emisphere would have been limited to evaluating each of the active arms against only the placebo for statistical significance.
Based on the current enrollment rate, the company expects to complete the additional enrollment within the next few weeks.
“Expanding our trial enrollment will give us a more robust data set to compare the three different dosing regimens of oral insulin being tested in this trial,” commented Dr Michael Goldberg, chairman and CEO of Emisphere Technologies. “We are pleased with the safety and activities observed to date, and are delighted that the DCGI granted us permission to increase enrollment.”